🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

✨Mulțumesc, România. 🇷🇴 Thank you, Romania!

Treatment Algorithm series: Small Cell #LungCancer w/ Ticiana Batista (Leal) ✅ Limited Stage ✅ Extensive Stage ✅ Role of PCI ✅ Upcoming data at #ASCO25 Full discussion: ⭐️ Oncbrothers.com/sclc-2025 ⭐️ Also on the “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates

We have previously described a novel plasma proteomic predictor for immunotherapy of NSCLC. doi.org/10.1200/PO.23.… At AACR 2025 we present the biological rationale and function of these proteins. Potential broad therapeutic implications doi.org/10.1158/1538-7… International Society of Liquid Biopsy

#IMforte phase 3 study in ES-SCLC— Maintenance lurbinectedin + atezolizumab v atezolizumab ▫️PFS: 5.4 v 2.1 mo (HR 0.54) ▫️OS: 13.2 v 10.6 mo (HR 0.73) ▫️Grade 3/4 AEs: 25.6% v 5.8% ▫️Tx discontinuation 2/2 AEs: 6.2% v 3.3% Practice-changing? OncoAlert SmallCellSMASHERS #ASCO25

This ASCO is definitely going to be different for me. A true honor to serve as a discussant and represent Brazil. I’ll be speaking on June 1st (and probably shivering) about the EGFR exon 20 insertions and HER2 mutations treatment scenario in NSCLC after the talks of Herbert Loong, MBBS, FASCO

Brief report JTO & JTO CRR on pregnancy and healthy baby on lorlatinib for #ALK NSCLC. Lorlatinib held weeks 4-20, then resumed. At 20m post-partum, ongoing PR & no congenital abnormalities in baby despite PK showing placental transfer of lorlatinib. jto.org/article/S1556-…

S2414 is the only early-stage #NSCLC trial testing whether adjuvant IO therapy provides added benefit when patients have already had pathCR to neoadjuvant chemo-immunotherapy. #NSCLC #lcsm Co-PI: Raymond Osarogiagbon, MBBS, FACP TM Chair: Bruna Pellini, MD Moffitt Cancer Center swog.org/clinical-trial…

🚨 #LiquidBiopsy in the spotlight at #ASCO25! From early detection to MRD and real-time monitoring, groundbreaking presentations are highlighting how LB is advancing into clinical practice 📍 Don’t miss them! Stay tuned 🔬 ASCO International Society of Liquid Biopsy The James RolfoLab

S2414 is the only early-stage #NSCLC trial testing whether adjuvant IO therapy provides added benefit when patients have already had pathCR to neoadjuvant chemo-immunotherapy. Co-PI: Raymond Osarogiagbon, MBBS, FACP TM Chair: Bruna Pellini, MD Moffitt Cancer Center swog.org/clinical-trial… @theCTSU

👋 Hello, Chicago! Looking forward to connecting with friends & colleagues around the 🌎

During #ASCO25, Bruna Pellini, MD (Bruna Pellini, MD) leads the session on non-small cell metastatic lung cancer. Tune in for a high-impact discussion on emerging research, clinical relevance and what's next for metastatic NSCLC care. Learn more: meetings.asco.org/2025-asco-annu…

#ASCO25 connecting friends for many years! ⭐️ Moffitt Cancer Center ASCO

Proud of Kaushal Parikh for the ASCO Conquer Cancer, the ASCO Foundation CDA Award! Couldn’t be any prouder than I am ☺️ Aaron Mansfield Mayo Clinic Comprehensive Cancer Center Mayo Clinic

📣 So proud of my mentee Keishla Arce for her Conquer Cancer Medical Student Rotation Award 👏🏼👏🏼This Conquer Cancer, the ASCO Foundation award will fund her rotation at Moffitt Cancer Center! Watch out for her application this year #IMresidency programs, Keishla is a #TrailBlazer ✨#ASCO25

📣The besties finally meet 🤩 Eric K. Singhi, MD #ASCO25

Is frontline combination therapy ALWAYS the right option for our newly diagnosed patients with EGFR+ NSCLC? Julia Rotow MD encourages us to think about: ◽️Comorbidities & Healthcare access ◽️Lower risk disease ◽️Patient preference & QOL #ASCO25 ASCO

#ASCO25 living guidelines Moffitt Cancer Center

Tomorrow at #ASCO25: Join two of Moffitt’s leading experts—Bruna Pellini, MD, (Bruna Pellini, MD), as she chairs a key session on metastatic non-small cell lung cancer, and Christine Chung, MD, as she presents new findings on head and neck squamous cell carcinoma. Follow

What’s next for lung cancer treatment? At #ASCO25, Bruna Pellini, MD, (Bruna Pellini, MD) and Patrick Hwu, MD, (Dr. Patrick Hwu), Moffitt’s President and CEO, shared insights on promising lung cancer research and how it’s driving new hope for patients and progress in the field.